Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $130
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $215 to $130.
Follow the latest Twist Bioscience Corporation (TWST) news and market headlines alongside the live TWST price. Stay informed on what's moving TWST.
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and lowers the price target from $215 to $130.
Analysts raised CrowdStrike and Jazz targets, while cutting targets for Cisco, Fermi, Twist Bioscience, Applied Materials, Firefly and Nebius.
Leerink Partners analyst Puneet Souda maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price target from $190 to $175.
TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and lowers the price target from $190 to $137.
Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and lowers the price target from $205 to $150.
Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and lowers the price target from $187 to $135.
Twist Bioscience reported Q4 2026 revenue growth of 28% YoY to $126.6M, with AI drug discovery revenue surging 175% to $59.1M. The company achieved positive adjusted EBITDA and plans to expand its DNA synthesis capacity from 10 to 16 writers. Management expects FY2027 revenue of $550-560M (21% growth) and will reinvest profits into capacity and automation rather than seeking external funding.
Twist Bioscience (TWST) shares fell Thursday after a 2027 outlook signaled slower AI drug discovery growth, overshadowing a strong Q4 beat.
Twist Bioscience (NASDAQ:TWST) reported fourth-quarter financial results on Thursday. The transcript from the company’s fourth-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Twist Bioscience (NASDAQ:TWST) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 28.89 percent increase over losses of $(0.45) per share from
Twist Bioscience (NASDAQ:TWST) sees FY2027 sales of $550.000 million-$560.000 million vs $547.137 million analyst estimate.
Twist Bioscience (NASDAQ:TWST) sees Q1 sales of $130.000 million-$132.000 million vs $126.354 million analyst estimate.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to TWST, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.